Cardinal Health nearing $6 billion purchase of Medtronic’s medical supplies unit

Cardinal Health is in exclusive talks to acquire the medical supplies business of Medtronic for $6 billion, sources told Reuters on April 5.

Those talks could result in a deal being finalized and announced later this month, though the same sources told Reuters it’s possible negotiations could end without any agreement.

Much of Medtronic’s business selling syringes, catheters, surgical instruments and other supplies came from its $50 billion purchase of Covidien in 2015. Bloomberg had reported earlier this year that Medtronic was shopping around the supplies unit with an expected value of around $5 billion, with the business’s earnings before interest, taxes, depreciation and amortization hovering around $500 million.

If Cardinal Health ends up being the buyer, the company would be expanding its supplies business following its 2015 acquisition of Johnson & Johnson’s Cordis portfolio, which included catheters, guidewires, vena cava filters, biliary stents and other devices.

Both Cardinal and Medtronic declined to comment to Reuters about the rumored sale. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.